Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

BACKGROUND: Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in elderly populations of industrialised countries. Bevacizumab (Avastin®) and ranibizumab (Lucentis®) are targeted biological drugs (a monoclonal antibody) that inhibit vascular endothelial growth...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cochrane Database Syst Rev
Main Authors: Moja, Lorenzo, Lucenteforte, Ersilia, Kwag, Koren H, Bertele, Vittorio, Campomori, Annalisa, Chakravarthy, Usha, D’Amico, Roberto, Dickersin, Kay, Kodjikian, Laurent, Lindsley, Kristina, Loke, Yoon, Maguire, Maureen, Martin, Daniel F, Mugelli, Alessandro, Mühlbauer, Bernd, Püntmann, Isabel, Reeves, Barnaby, Rogers, Chris, Schmucker, Christine, Subramanian, Manju L, Virgili, Gianni
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4262120/
https://ncbi.nlm.nih.gov/pubmed/25220133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD011230.pub2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados